Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Qiagen ( (QGEN) ) has issued an announcement.
Qiagen N.V. has been informed by the Netherlands Authority for the Financial Markets (AFM) about a notification regarding its voting rights, primarily involving BlackRock, Inc. The notification details the distribution of shares and voting rights held indirectly by BlackRock through various subsidiaries. This announcement highlights BlackRock’s significant capital interest and voting rights in Qiagen, indicating a notable stakeholder influence in the company’s governance.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products that enable customers to gain valuable insights from biological samples, with a market focus on advancing healthcare and research.
Average Trading Volume: 1,469,339
Technical Sentiment Signal: Buy
Current Market Cap: $11.04B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.